Please Wait a Moment
X

CTS History

01Dec

Babesia

SuperUser Account |01 Dec, 2015 | Return|

In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.

About the Author

Related

On-time test results

On-time test results

Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...

Read More >
CTS implements licensesd Zika test

CTS implements licensesd Zika test

Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...

Read More >
Source Plasma / Blood Donor Testing

Source Plasma / Blood Donor Testing

In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).

Read More >
Assay Conversion

Assay Conversion

In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...

Read More >
CTS Business Continuity Plan

CTS Business Continuity Plan

As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...

Read More >
Pooled Babesia

Pooled Babesia

Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...

Read More >